← All trials
NCT05355350
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2022
- Primary completion
- Jan 1, 2026
- Completion date
- Jun 1, 2026
- First posted
- May 2, 2022
- Last posted
- Jul 28, 2022
- Enrollment
- 1000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Technion UniversityLead sponsor
- Hebrew UniversityCollaborator
- Tel Aviv UniversityCollaborator
- Technion UniversityOverall official - principal investigator
- Technion UniversityReponsible party - principal investigator
- Technion UniversityStudy director
- Tel Aviv UniversityCollaborator
- Technion UniversitySponsor investigator
- Technion UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.